Heterogeneity on long-term disability trajectories in patients with secondary progressive MS: a latent class analysis from Big MS Data network.

Signori A; Lorscheider J; Vukusic S; Trojano M; Iaffaldano P; Hillert J; Hyde R; Pellegrini F; Magyari M; Koch-Henriksen N; Sørensen PS; Spelman T; van der Walt A; Horakova D; Havrdova E; Girard M; Eichau S; Grand'Maison F; Gerlach O; Terzi M; Ozakbas S; Skibina O; Van Pesch V; Sa MJ; Prevost J; Alroughani R; McCombe PA; Gouider R; Mrabet S; Castillo-Trivino T; Zhu C; de Gans K; Sánchez-Menoyo JL; Yamout B; Khoury S; Sormani MP; Kalincik T; Butzkueven H; Big MS Data Network. Journal of neurology, neurosurgery, and psychiatry. 2023.

Recurrent disability progression endpoints in multiple sclerosis clinical trials.

Bühler A; Wolbers M; Model F; Wang Q; Belachew S; Manfrini M; Lorscheider J; Kappos L; Beyersmann J. Multiple sclerosis (Houndmills, Basingstoke, England). 2023.

Reliability and acceptance of dreaMS, a software application for people with multiple sclerosis: a feasibility study.

Woelfle T; Pless S; Reyes O; Wiencierz A; Feinstein A; Calabrese P; Gugleta K; Kappos L; Lorscheider J; Naegelin Y. Journal of neurology. 2023.

Serum Glial Fibrillary Acidic Protein Compared With Neurofilament Light Chain as a Biomarker for Disease Progression in Multiple Sclerosis.

Meier S; Willemse EAJ; Schaedelin S; Oechtering J; Lorscheider J; Melie-Garcia L; Cagol A; Barakovic M; Galbusera R; Subramaniam S; Barro C; Abdelhak A; Thebault S; Achtnichts L; Lalive P; Müller S; Pot C; Salmen A; Disanto G; Zecca C; D'Souza M; Orleth A; Khalil M; Buchmann A; Du Pasquier R; Yaldizli Ö; Derfuss T; Berger K; Hermesdorf M; Wiendl H; Piehl F; Battaglini M; Fischer U; Kappos L; Gobbi C; Granziera C; Bridel C; Leppert D; Maleska Maceski A; Benkert P; Kuhle J. JAMA neurology. 2023.

Synthesizing cross-design evidence and cross-format data using network meta-regression.

Hamza T; Chalkou K; Pellegrini F; Kuhle J; Benkert P; Lorscheider J; Zecca C; Iglesias-Urrutia CP; Manca A; Furukawa TA; Cipriani A; Salanti G. Research synthesis methods. 2023.

Association of Brain Atrophy With Disease Progression Independent of Relapse Activity in Patients With Relapsing Multiple Sclerosis.

Cagol A; Schaedelin S; Barakovic M; Benkert P; Todea RA; Rahmanzadeh R; Galbusera R; Lu PJ; Weigel M; Melie-Garcia L; Ruberte E; Siebenborn N; Battaglini M; Radue EW; Yaldizli Ö; Oechtering J; Sinnecker T; Lorscheider J; Fischer-Barnicol B; Müller S; Achtnichts L; Vehoff J; Disanto G; Findling O; Chan A; Salmen A; Pot C; Bridel C; Zecca C; Derfuss T; Lieb JM; Remonda L; Wagner F; Vargas MI; Du Pasquier R; Lalive PH; Pravatà E; Weber J; Cattin PC; Gobbi C; Leppert D; Kappos L; Kuhle J; Granziera C. JAMA neurology. 2022.

Endovascular Treatment for Acute Ischemic Stroke With or Without General Anesthesia: A Matched Comparison.

Wagner B; Lorscheider J; Wiencierz A; Blackham K; Psychogios M; Bolliger D; De Marchis GM; Engelter ST; Lyrer P; Wright PR; Fischer U; Mordasini P; Nannoni S; Puccinelli F; Kahles T; Bianco G; Carrera E; Luft AR; Cereda CW; Kägi G; Weber J; Nedeltchev K; Michel P; Gralla J; Arnold M; Bonati LH; Swiss Stroke Registry Investigators. Stroke. 2022.

Serum neurofilament light chain for individual prognostication of disease activity in people with multiple sclerosis: a retrospective modelling and validation study.

Benkert P; Meier S; Schaedelin S; Manouchehrinia A; Yaldizli Ö; Maceski A; Oechtering J; Achtnichts L; Conen D; Derfuss T; Lalive PH; Mueller C; Müller S; Naegelin Y; Oksenberg JR; Pot C; Salmen A; Willemse E; Kockum I; Blennow K; Zetterberg H; Gobbi C; Kappos L; Wiendl H; Berger K; Sormani MP; Granziera C; Piehl F; Leppert D; Kuhle J; NfL Reference Database in the Swiss Multiple Sclerosis Cohort Study Group. The Lancet. Neurology. 2022.

Accurate classification of secondary progression in multiple sclerosis using a decision tree.

Ramanujam R; Zhu F; Fink K; Karrenbauer VD; Lorscheider J; Benkert P; Kingwell E; Tremlett H; Hillert J; Manouchehrinia A; BeAMS Study group. Multiple sclerosis (Houndmills, Basingstoke, England). 2021.

Acute Polyradiculomyelitis With Spinal Cord Gray Matter Lesions: A Report of Two Cases.

Tsagkas C; Wendebourg MJ; Mehling M; Lorscheider J; Lyrer P; Décard BF. Frontiers in neurology. 2021.

Combination of teriflunomide and interferon as follow-up therapy after fingolimod-associated PML

Fischer-Barnicol B.; Oechtering J.; Kuhle J.; Lorscheider J.; Kappos L.; Derfuss T.. Neurology-Neuroimmunology & Neuroinflammation. 2021.

Comparative analysis of dimethyl fumarate and fingolimod in relapsing-remitting multiple sclerosis.

Lorscheider J; Benkert P; Lienert C; Hänni P; Derfuss T; Kuhle J; Kappos L; Yaldizli Ö. Journal of neurology. 2021.

Disability progression in relapse-free multiple sclerosis patients on fingolimod versus interferon-beta/glatiramer acetate.

von Wyl V; Benkert P; Moser A; Lorscheider J; Décard B; Hänni P; Lienert C; Kuhle J; Derfuss T; Kappos L; Yaldizli Ö. Multiple sclerosis (Houndmills, Basingstoke, England). 2021.

Practice Effects of Mobile Tests of Cognition, Dexterity, and Mobility on Patients With Multiple Sclerosis: Data Analysis of a Smartphone-Based Observational Study.

Woelfle T; Pless S; Wiencierz A; Kappos L; Naegelin Y; Lorscheider J. Journal of medical Internet research. 2021.

When does a heap become a heap?

Lorscheider J. . 2021.

Electronic Neurostatus-EDSS increases the quality of expanded disability status scale assessments: Experience from two phase 3 clinical trials.

D'Souza M; Heikkilä A; Lorscheider J; Haller V; Kravalis K; Gysin S; Fuertes NAC; Fricker E; Lam E; Higgins P; Tomic D; Papadopoulou A; Kappos L. Multiple sclerosis (Houndmills, Basingstoke, England). 2020.

Influence of age at disease onset on future relapses and disability progression in patients with multiple sclerosis on immunomodulatory treatment.

von Wyl V; Décard BF; Benkert P; Lorscheider J; Hänni P; Lienert C; Kuhle J; Derfuss T; Kappos L; Yaldizli Ö. European journal of neurology. 2020.

A case of progressive multifocal leukoencephalopathy under dimethyl fumarate treatment without severe lymphopenia or immunosenescence.

Diebold M; Altersberger V; Décard BF; Kappos L; Derfuss T; Lorscheider J. Multiple sclerosis (Houndmills, Basingstoke, England). 2019.

Anti-inflammatory disease-modifying treatment and disability progression in primary progressive multiple sclerosis: a cohort study.

Lorscheider J; Kuhle J; Izquierdo G; Lugaresi A; Havrdova E; Horakova D; Hupperts R; Duquette P; Girard M; Prat A; Grand'Maison F; Grammond P; Sola P; Ferraro D; Trojano M; Ramo-Tello C; Lechner-Scott J; Pucci E; Solaro C; Slee M; Van Pesch V; Sanchez Menoyo JL; van der Walt A; Butzkueven H; Kappos L; Kalincik T; MSBase Study Group. European journal of neurology. 2019.

Association of Rituximab Treatment With Disability Progression Among Patients With Secondary Progressive Multiple Sclerosis.

Naegelin Y; Naegelin P; von Felten S; Lorscheider J; Sonder J; Uitdehaag BMJ; Scotti B; Zecca C; Gobbi C; Kappos L; Derfuss T. JAMA neurology. 2019.

Hypothyroidism manifesting as multiple cranial neuropathies: a case report.

Hepprich M; Lorscheider J; Peters N; Betz MJ. Journal of medical case reports. 2019.

PML with dimethyl fumarate-No convincing case against natalizumab.

Diebold M; Altersberger V; Décard BF; Kappos L; Derfuss T; Lorscheider J. Multiple sclerosis (Houndmills, Basingstoke, England). 2019.

Comparative analysis of natalizumab versus fingolimod as second-line treatment in relapsing-remitting multiple sclerosis.

Lorscheider J; Benkert P; Lienert C; Hänni P; Derfuss T; Kuhle J; Kappos L; Yaldizli Ö. Multiple sclerosis (Houndmills, Basingstoke, England). 2018.

Anti-inflammatory disease-modifying treatment and short-term disability progression in SPMS.

Lorscheider J; Jokubaitis VG; Spelman T; Izquierdo G; Lugaresi A; Havrdova E; Horakova D; Trojano M; Duquette P; Girard M; Prat A; Grand'Maison F; Grammond P; Pucci E; Boz C; Sola P; Ferraro D; Spitaleri D; Lechner-Scott J; Terzi M; Van Pesch V; Iuliano G; Bergamaschi R; Ramo-Tello C; Granella F; Oreja-Guevara C; Butzkueven H; Kalincik T; MSBase Study Group. Neurology. 2017.

Defining secondary progressive multiple sclerosis.

Lorscheider J; Buzzard K; Jokubaitis V; Spelman T; Havrdova E; Horakova D; Trojano M; Izquierdo G; Girard M; Duquette P; Prat A; Lugaresi A; Grand'Maison F; Grammond P; Hupperts R; Alroughani R; Sola P; Boz C; Pucci E; Lechner-Scott J; Bergamaschi R; Oreja-Guevara C; Iuliano G; Van Pesch V; Granella F; Ramo-Tello C; Spitaleri D; Petersen T; Slee M; Verheul F; Ampapa R; Amato MP; McCombe P; Vucic S; Sánchez Menoyo JL; Cristiano E; Barnett MH; Hodgkinson S; Olascoaga J; Saladino ML; Gray O; Shaw C; Moore F; Butzkueven H; Kalincik T; MSBase Study Group. Brain : a journal of neurology. 2016.

Predictors of long-term disability accrual in relapse-onset multiple sclerosis.

Jokubaitis VG; Spelman T; Kalincik T; Lorscheider J; Havrdova E; Horakova D; Duquette P; Girard M; Prat A; Izquierdo G; Grammond P; Van Pesch V; Pucci E; Grand'Maison F; Hupperts R; Granella F; Sola P; Bergamaschi R; Iuliano G; Spitaleri D; Boz C; Hodgkinson S; Olascoaga J; Verheul F; McCombe P; Petersen T; Rozsa C; Lechner-Scott J; Saladino ML; Farina D; Iaffaldano P; Paolicelli D; Butzkueven H; Lugaresi A; Trojano M; MSBase Study Group. Annals of neurology. 2016.

The Swiss Multiple Sclerosis Cohort-Study (SMSC): A prospective Swiss wide investigation of key phases in disease evolution and new treatment options

Disanto G.; Benkert P.; Lorscheider J.; Mueller S.; Vehoff J.; Zecca C.; Ramseier S.; Achtnichts L.; Findling O.; Nedeltchev K.; Radue E.-W.; Sprenger T.; Stippich C.; Derfuss T.; Louvion J.-F.; Kamm C.P.; Mattle H.P.; Lotter C.; Du Pasquier R.; Schluep M.; Pot C.; Lalive P.H.; Yaldizli O.; Gobbi C.; Kappos L.; Kuhle J.; Saxer J.; Remonda L.; Boxheimer L.; Limberg M.; Scheerer I.; Orleth A.; Treppke F.; Beregi E.; Reinhardt J.; Fellner I.; Wurfel J.; Thoeni A.; Palatini A.; Pauli-Magnus C.; Fabbro T.; Roesler A.; Mechati S.; Chan A.; Salmen A.; Kaeser M.; Wagner F.; Verma R.; Di Marco M.; Haller S.; Lovblad K.-O.; Granziera C.; Hagmann P.; Maeder P.; Tschuor S.; Cianfoni A.; Weber J.. PLoS One. 2016.

Fingolimod and CSF neurofilament light chain levels in relapsing-remitting multiple sclerosis.

Kuhle J; Disanto G; Lorscheider J; Stites T; Chen Y; Dahlke F; Francis G; Shrinivasan A; Radue EW; Giovannoni G; Kappos L. Neurology. 2015.

T-cell response against varicella-zoster virus in fingolimod-treated MS patients.

Ricklin,Meret E; Lorscheider,Johannes; Waschbisch,Anne; Paroz,Cecile; Mehta,Satish K; Pierson,Duane L; Kuhle,Jens; Fischer-Barnicol,Bettina; Sprenger,Till; Lindberg,Raija L P; Kappos,Ludwig; Derfuss,Tobias. Neurology. 2013.

The BAR domain protein PICK1 regulates cell recognition and morphogenesis by interacting with Neph proteins.

Höhne M; Lorscheider J; von Bardeleben A; Dufner M; Scharf MA; Gödel M; Helmstädter M; Schurek EM; Zank S; Gerke P; Kurschat C; Sivritas SH; Neumann-Haefelin E; Huber TB; Reinhardt HC; Schauss AC; Schermer B; Fischbach KF; Benzing T. Molecular and Cellular Biology. 2011.